<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>548</serviceExecutionTime><Drug id="3735"><DrugName>octreotide acetate (long-acting formulation), Novartis</DrugName><DrugNamesKey><Name id="42766690">Sandostatin LAR Depot</Name><Name id="43005867">Sandostatin LP</Name><Name id="42756070">octreotide</Name><Name id="42756072">octreotide acetate</Name></DrugNamesKey><DrugSynonyms><Name><Value>octreotide</Value><Types><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>octreotide acetate</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Sandostatin LAR</Value></Name><Name><Value>Sandostatin LAR Depot</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>octreotide pamoate</Value></Name><Name><Value>octreotide acetate (long-acting formulation), Novartis</Value></Name><Name><Value>octreotide LAR</Value></Name><Name><Value>Sandostatin LP</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>83150-76-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>79517-01-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesPrimary><Company id="23137">Novartis AG</Company></CompaniesPrimary><CompaniesSecondary><Company id="16018">Novartis Pharma KK</Company><Company id="17278">Italfarmaco SpA</Company><Company id="24481">Sandoz Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="3735" type="Drug"><TargetEntity id="120090" type="siDrug">Octreotide acetate</TargetEntity></SourceEntity><SourceEntity id="16018" type="Company"><TargetEntity id="4296010314" type="organizationId">Novartis Pharma KK</TargetEntity></SourceEntity><SourceEntity id="17278" type="Company"><TargetEntity id="4296367507" type="organizationId">Italfarmaco SpA</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="24481" type="Company"><TargetEntity id="4297283322" type="organizationId">Sandoz Pharmaceuticals AG</TargetEntity></SourceEntity><SourceEntity id="102" type="ciIndication"><TargetEntity id="10012735" type="MEDDRA"/><TargetEntity id="D003967" type="MeSH"/><TargetEntity id="-957779542" type="omicsDisease"/><TargetEntity id="380" type="siCondition"/></SourceEntity><SourceEntity id="110" type="ciIndication"><TargetEntity id="R11.1" type="ICD10"/><TargetEntity id="10047700" type="MEDDRA"/><TargetEntity id="D014839" type="MeSH"/></SourceEntity><SourceEntity id="1128" type="ciIndication"><TargetEntity id="C7A" type="ICD10"/><TargetEntity id="209" type="ICD9"/><TargetEntity id="10052399" type="MEDDRA"/><TargetEntity id="D018358" type="MeSH"/><TargetEntity id="-1333045072" type="omicsDisease"/><TargetEntity id="1422" type="siCondition"/></SourceEntity><SourceEntity id="1667" type="ciIndication"><TargetEntity id="10018265" type="MEDDRA"/><TargetEntity id="D005877" type="MeSH"/><TargetEntity id="-948761126" type="omicsDisease"/><TargetEntity id="5361" type="siCondition"/></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="2168" type="ciIndication"><TargetEntity id="10049416" type="MEDDRA"/><TargetEntity id="D012778" type="MeSH"/><TargetEntity id="104008" type="ORPHANET"/><TargetEntity id="-127143153" type="omicsDisease"/><TargetEntity id="403" type="siCondition"/></SourceEntity><SourceEntity id="2179" type="ciIndication"><TargetEntity id="10057165" type="MEDDRA"/><TargetEntity id="265" type="siCondition"/></SourceEntity><SourceEntity id="2212" type="ciIndication"><TargetEntity id="K76.7" type="ICD10"/><TargetEntity id="10019846" type="MEDDRA"/><TargetEntity id="D006530" type="MeSH"/><TargetEntity id="-772211452" type="omicsDisease"/><TargetEntity id="433" type="siCondition"/></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"/><TargetEntity id="10033609" type="MEDDRA"/><TargetEntity id="D010190" type="MeSH"/><TargetEntity id="-670361033" type="omicsDisease"/><TargetEntity id="630" type="siCondition"/></SourceEntity><SourceEntity id="2939" type="ciIndication"><TargetEntity id="10043670" type="MEDDRA"/><TargetEntity id="D013945" type="MeSH"/><TargetEntity id="99867" type="ORPHANET"/><TargetEntity id="-2144850506" type="omicsDisease"/><TargetEntity id="2566" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="5" type="ciIndication"><TargetEntity id="10000599" type="MEDDRA"/><TargetEntity id="D000172" type="MeSH"/><TargetEntity id="963" type="ORPHANET"/><TargetEntity id="-945923203" type="omicsDisease"/><TargetEntity id="525" type="siCondition"/></SourceEntity><SourceEntity id="54" type="ciIndication"><TargetEntity id="D002277" type="MeSH"/><TargetEntity id="-233893258" type="omicsDisease"/><TargetEntity id="665" type="siCondition"/></SourceEntity><SourceEntity id="576" type="ciIndication"><TargetEntity id="10012689" type="MEDDRA"/><TargetEntity id="D003930" type="MeSH"/><TargetEntity id="-521804723" type="omicsDisease"/><TargetEntity id="795" type="siCondition"/></SourceEntity><SourceEntity id="3272" type="Action"><TargetEntity id="582" type="Mechanism">Growth Hormone Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="1120" type="Action"><TargetEntity id="306" type="Mechanism">Somatostatin Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Diarrhea - US - Oct-1988</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="102">Diarrhea</Indication><Indication id="1128">Neuroendocrine tumor</Indication><Indication id="1667">Gigantism</Indication><Indication id="5">Acromegaly</Indication><Indication id="54">Carcinoma</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="110">Emesis</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="2168">Short bowel syndrome</Indication><Indication id="2179">Varices</Indication><Indication id="2212">Hepatorenal syndrome</Indication><Indication id="238">Obesity</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="2939">Thymoma</Indication><Indication id="49">Breast tumor</Indication><Indication id="576">Diabetic retinopathy</Indication></IndicationsSecondary><ActionsPrimary><Action id="1120">Somatostatin receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="4007">Antidiarrhoeal</Action><Action id="62253">Anticancer hormone</Action><Action id="3272">Growth hormone release inhibitor</Action><Action id="1545">Anticancer</Action><Action id="2970">Anti-emetic</Action></ActionsSecondary><Technologies><Technology id="745">Suspension</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="651">Intramuscular formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra><Ephmra><Code>A7</Code><Name>ANTIDIARRHOEALS, ORAL ELECTROLYTE REPLACERS AND INTESTINAL ANTI-INFLAMMATORIES</Name></Ephmra><Ephmra><Code>A4</Code><Name>ANTIEMETICS AND ANTINAUSEANTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-02-08T17:18:43.000Z</LastModificationDate><ChangeDateLast>2019-02-11T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; and its subsidiary &lt;ulink linkID="1017404" linkType="Company"&gt;Sandoz&lt;/ulink&gt; has developed a long-acting release formulation of its somatostatin analog &lt;ulink linkID="78778" linkType="Drug"&gt;octreotide&lt;/ulink&gt; (octreotide acetate;  Sandostatin LAR; Sandostatin LAR Depot; Sandostatin LP)  available as pre-filled syringe/ vial ampoule [&lt;ulink linkID="487493" linkType="Reference"&gt;487493&lt;/ulink&gt;], [&lt;ulink linkID="990832" linkType="Reference"&gt;990832&lt;/ulink&gt;], [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]. In the US, the product is indicated for long-term maintenance therapy in acromegalic patients for whom Sandostatin injection is appropriate, for severe diarrhea and flushing episodes associated with metastatic carcinoid tumors, and for  profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-tumors (VIPomas)  [&lt;ulink linkID="1303533" linkType="Reference"&gt;1303533&lt;/ulink&gt;]. In the EU, the product is indicated for the treatment of acromegaly and gastorenteropancreatic (GEP) tumors, including  carcinoid tumors with features of carcinoid syndrome, vipomas and glucagonomas  [&lt;ulink linkID="776665" linkType="Reference"&gt;776665&lt;/ulink&gt;]. In Japan, the product is indicated for acromegaly, pituitary gigantism, for the improvement of symptoms associated with VIP-producing tumor, carcinoid tumor and gastrin-producing tumor that shows the features of the carcinoid syndrome, and for  gastrointestinal neuroendocrine tumors [&lt;ulink linkID="1301752" linkType="Reference"&gt;1301752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sandostatin LAR Depot was first launched in Germany in December 1997 for the treatment of acromegaly [&lt;ulink linkID="1583175" linkType="Reference"&gt;1583175&lt;/ulink&gt;]. In 1998, Sandostatin LAR was approved throughout Europe for the treatment of acromegaly and gastorenteropancreatic (GEP) endocrine tumors  [&lt;ulink linkID="776665" linkType="Reference"&gt;776665&lt;/ulink&gt;]. The product was launched for acromegaly in the US in January 1999 [&lt;ulink linkID="311466" linkType="Reference"&gt;311466&lt;/ulink&gt;], [&lt;ulink linkID="322224" linkType="Reference"&gt;322224&lt;/ulink&gt;]. By June 1999, it had been launched in the US for GEP tumors, the UK for GEP tumors,  Italy and France for acromegaly and GEP tumors,  and Spain for acromegaly [&lt;ulink linkID="328007" linkType="Reference"&gt;328007&lt;/ulink&gt;], [&lt;ulink linkID="328281" linkType="Reference"&gt;328281&lt;/ulink&gt;].  In June 2004, Sandostatin LAR was launched in Japan for the treatment acromegaly, pituitary gigantism and the symptoms associated with GI hormone-producing tumors [&lt;ulink linkID="537736" linkType="Reference"&gt;537736&lt;/ulink&gt;], [&lt;ulink linkID="1229980" linkType="Reference"&gt;1229980&lt;/ulink&gt;]. In November 2011, approval was granted in Japan for gastrointestinal neuroendocrine tumors [&lt;ulink linkID="1243211" linkType="Reference"&gt;1243211&lt;/ulink&gt;]; it was presumed that the product was launched for this indication shortly after approval.  &lt;/para&gt;&lt;para&gt;Novartis was previously developing  Sandostatin LAR for the potential treatment of proliferative diabetic retinopathy, hepatocellular carcinoma, variceal bleeding, short bowel syndrome (SBS), hepatocellular syndrome, emesis in patients with inoperable bowel obstruction, thymoma and pediatric obesity. The formulation had reached phase III trials for proliferative diabetic retinopathy by 1999 [&lt;ulink linkID="319337" linkType="Reference"&gt;319337&lt;/ulink&gt;], and these were ongoing in early 2006 [&lt;ulink linkID="654396" linkType="Reference"&gt;654396&lt;/ulink&gt;], [&lt;ulink linkID="651122" linkType="Reference"&gt;651122&lt;/ulink&gt;], [&lt;ulink linkID="652670" linkType="Reference"&gt;652670&lt;/ulink&gt;];  however, in April 2006, Novartis revealed that it had terminated the development of the compound for proliferative diabetic retinopathy [&lt;ulink linkID="663540" linkType="Reference"&gt;663540&lt;/ulink&gt;]. By February 2006, two phase IV trials in pediatric patients with hypothalamic obesity had completed [&lt;ulink linkID="1302616" linkType="Reference"&gt;1302616&lt;/ulink&gt;], [&lt;ulink linkID="1303086" linkType="Reference"&gt;1303086&lt;/ulink&gt;]. By December 2007, a phase II/III combination trial in patients with hepatorenal syndrome had completed and in May 2005, preliminary data from a phase III trial in hepatocellular carcinoma were reported [&lt;ulink linkID="602913" linkType="Reference"&gt;602913&lt;/ulink&gt;], [&lt;ulink linkID="1302741" linkType="Reference"&gt;1302741&lt;/ulink&gt;]. In September 2008, the phase II  trial of  emesis in patients with inoperable bowel obstruction had completed [&lt;ulink linkID="1303259" linkType="Reference"&gt;1303259&lt;/ulink&gt;]. In October 2010, a phase II trial in patients with primary inoperable thymoma had completed [&lt;ulink linkID="1302719" linkType="Reference"&gt;1302719&lt;/ulink&gt;]. In May 2001, data were reported for a trial in variceal bleeding [&lt;ulink linkID="408782" linkType="Reference"&gt;408782&lt;/ulink&gt;], [&lt;ulink linkID="412150" linkType="Reference"&gt;412150&lt;/ulink&gt;]. In May 2000, results were presented from a trial in patients with SBS  [&lt;ulink linkID="366380" linkType="reference"&gt;366380&lt;/ulink&gt;]. However, no further development had been reported for these indications for some time. &lt;/para&gt;&lt;para&gt;By January 2013, Sandostatin LAR was approved in 26 countries as a new formulation, including a new diluent, safety needle and vial adapter to improve  mixing and administration [&lt;ulink linkID="1388709" linkType="Reference"&gt;1388709&lt;/ulink&gt;]. In February 2014, an intramuscular injection kit formulation of Sandostatin LAR was approved in Japan [&lt;ulink linkID="1525477" linkType="Reference"&gt;1525477&lt;/ulink&gt;]; in June 2014, the kit was launched [&lt;ulink linkID="1574010" linkType="Reference"&gt;1574010&lt;/ulink&gt;]. In July 2014, the kit was approved in the US and would be launched in 1Q15 [&lt;ulink linkID="1225517" linkType="Reference"&gt;1225517&lt;/ulink&gt;]; the kit was was presumably launched as planned [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In the US, Sandostatin LAR formulation patents were reported to expire from the end of 2014 until January 2017, when the last formulation patent expired.  In countries outside the US, formulation patents  covering Sandostatin LAR expired in July 2010 [&lt;ulink linkID="654396" linkType="Reference"&gt;654396&lt;/ulink&gt;], [&lt;ulink linkID="1164651" linkType="Reference"&gt;1164651&lt;/ulink&gt;], [&lt;ulink linkID="1258232" linkType="Reference"&gt;1258232&lt;/ulink&gt;], [&lt;ulink linkID="1388709" linkType="Reference"&gt;1388709&lt;/ulink&gt;], [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]. In January 2014, Novartis reported that there were no approved generic versions of Sandostatin LAR in major markets at that time [&lt;ulink linkID="1528447" linkType="Reference"&gt;1528447&lt;/ulink&gt;]; in January 2018, that was still the case [&lt;ulink linkID="2004756" linkType="Reference"&gt;2004756&lt;/ulink&gt;]; in January 2019, Novartis noted that there was no patent protection in the US, EU and Japan, but at that time,  there was no generic competition for the drug in these major markets  [&lt;ulink linkID="2116311" linkType="Reference"&gt;2116311&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Sandostatin LAR Depot received marketing approval in the US in November 1998  [&lt;ulink linkID="311466" linkType="reference"&gt;311466&lt;/ulink&gt;]. The product was launched in the US in January 1999 for acromegaly [&lt;ulink linkID="322224" linkType="reference"&gt;322224&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2010, the drug received Orphan status from the FDA for neuroendocrine tumors [&lt;ulink linkID="1219114" linkType="Reference"&gt;1219114&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, the product had been additionally approved for the treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors; for the long-term treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-tumors (VIPomas) in patients in whom initial treatment with Sandostatin injection has been shown to be effective and tolerated; and for GI hormone-producing tumors and pituitary gigantism [&lt;ulink linkID="1303533" linkType="Reference"&gt;1303533&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2013, a filing for an intramuscular injection kit formulation of Sandostatin LAR was submitted for approval in the US [&lt;ulink linkID="1525477" linkType="Reference"&gt;1525477&lt;/ulink&gt;]. In July 2014, the kit, which includes a safety needle, new diluent, vial adaptor and smaller needle gauge, was approved in the US and would be launched in 1Q15 [&lt;ulink linkID="1225517" linkType="Reference"&gt;1225517&lt;/ulink&gt;]; the kit was was presumably launched as planned [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In June 1995, the drug was approved in France for acromegaly [&lt;ulink linkID="1288148" linkType="Reference"&gt;1288148&lt;/ulink&gt;]. Sandostatin LAR was launched in Germany in December 1997 for the treatment of acromegaly [&lt;ulink linkID="1583175" linkType="Reference"&gt;1583175&lt;/ulink&gt;], [&lt;ulink linkID="281429" linkType="reference"&gt;281429&lt;/ulink&gt;]. In 1998, Sandostatin LAR was approved throughout Europe for the treatment of acromegaly and GEP tumors, including  carcinoid tumors with features of carcinoid syndrome, vipomas and glucagonomas  [&lt;ulink linkID="776665" linkType="Reference"&gt;776665&lt;/ulink&gt;]. By June 1999, it had been launched in the UK for GEP tumors,  Italy and France for acromegaly and GEP tumors,  and Spain for acromegaly [&lt;ulink linkID="328007" linkType="Reference"&gt;328007&lt;/ulink&gt;], [&lt;ulink linkID="328281" linkType="Reference"&gt;328281&lt;/ulink&gt;].  By December 2002, the product was presumably available throughout Europe [&lt;ulink linkID="440183" linkType="Reference"&gt;440183&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In November 2002, Novartis filed an NDA in Japan for Sandostatin LAR for the treatment of acromegaly, pituitary gigantism and the symptoms associated with GI hormone-producing tumors [&lt;ulink linkID="469331" linkType="reference"&gt;469331&lt;/ulink&gt;]. In January 2004, the CDDS recommended approval of Sandostatin LAR for these indications [&lt;ulink linkID="522407" linkType="reference"&gt;522407&lt;/ulink&gt;]. The NDA was approved in Japan in April 2004 [&lt;ulink linkID="537736" linkType="reference"&gt;537736&lt;/ulink&gt;]. In June 2004, the product was launched [&lt;ulink linkID="1229980" linkType="Reference"&gt;1229980&lt;/ulink&gt;], [&lt;ulink linkID="1301752" linkType="Reference"&gt;1301752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, Novartis filed for approval for  the treatment of gastrointestinal neuroendocrine tumors. In November 2011,  the product (10, 20 and 30 mg) was approved for gastrointestinal neuroendocrine tumors [&lt;ulink linkID="1243211" linkType="Reference"&gt;1243211&lt;/ulink&gt;]; it was presumed that the product was launched for this indication shortly after approval. &lt;/para&gt;&lt;para&gt;By October 2013, a new formulation of the product had been filed for approval [&lt;ulink linkID="1494129" linkType="Reference"&gt;1494129&lt;/ulink&gt;]. In February 2014, a new user-friendly intramuscular kit formulation of Sandostatin LAR was approved in Japan, which included a vial filled with the product and an ampule containing the suspension dispersion liquid [&lt;ulink linkID="1525477" linkType="Reference"&gt;1525477&lt;/ulink&gt;]; in June 2014, the kit was launched [&lt;ulink linkID="1574010" linkType="Reference"&gt;1574010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In May 2013, Sandostatin LAR was approved in China for the treatment of acromegaly, pituitary gigantism and the symptoms associated with GI hormone-producing tumors [&lt;ulink linkID="1514537" linkType="Reference"&gt;1514537&lt;/ulink&gt;]. By January 2014, it had been launched there [&lt;ulink linkID="1514150" linkType="Reference"&gt;1514150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;By June 1999, Sandostatin LAR Depot had been launched in over 12 countries [&lt;ulink linkID="328007" linkType="reference"&gt;328007&lt;/ulink&gt;], [&lt;ulink linkID="328281" linkType="reference"&gt;328281&lt;/ulink&gt;], [&lt;ulink linkID="776665" linkType="Reference"&gt;776665&lt;/ulink&gt;]. By January 2012, the product had been approved in more than 100 countries  [&lt;ulink linkID="1258232" linkType="Reference"&gt;1258232&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By June 1999, Sandostatin LAR Depot had been launched in Canada [&lt;ulink linkID="328007" linkType="reference"&gt;328007&lt;/ulink&gt;], [&lt;ulink linkID="328281" linkType="reference"&gt;328281&lt;/ulink&gt;], [&lt;ulink linkID="776665" linkType="Reference"&gt;776665&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By June 1999, Sandostatin LAR Depot had been launched in Latin America [&lt;ulink linkID="328007" linkType="reference"&gt;328007&lt;/ulink&gt;], [&lt;ulink linkID="328281" linkType="reference"&gt;328281&lt;/ulink&gt;], [&lt;ulink linkID="776665" linkType="Reference"&gt;776665&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2012, the drug had been approved, and presumably launched, in Brazil [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By June 1999, Sandostatin LAR Depot had been launched in Hong Kong  [&lt;ulink linkID="328007" linkType="reference"&gt;328007&lt;/ulink&gt;], [&lt;ulink linkID="328281" linkType="reference"&gt;328281&lt;/ulink&gt;], [&lt;ulink linkID="776665" linkType="Reference"&gt;776665&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By February 2012, the drug had been approved, and presumably launched, in Australia [&lt;ulink linkID="2065870" linkType="Reference"&gt;2065870&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In May 2013, an open-label, multicenter, phase IV study (&lt;ulink linkID="109844" linkType="Protocol"&gt;NCT01789281&lt;/ulink&gt;; CRAD001C2X01B) to access to everolimus roll-over protocol in patients (expected n = 52) who have completed a previous Novartis-sponsored everolimus study and are judged by the investigator to benefit from continued everolimus treatment, was initiated in USA, Italy, Korea, Republic of, and Netherlands. At that time, the study was expected to complete in September 2022 [&lt;ulink linkID="1786153" linkType="Reference"&gt;1786153&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2007, data were presented at the 43rd ASCO meeting in Chicago, IL, from a phase III trial (RTOG-0315) to determine the efficacy of octreotide in preventing chemoradiation-induced diarrhea in patients with anal or rectal cancer. The study accrued 233 patients. There was no  significant difference in incidence of grade 2+ diarrhea,  with 52 (49%) and 48 (44%) cases in the placebo and octreotide acetate treatment arms, respectively [&lt;ulink linkID="797660" linkType="Reference"&gt;797660&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, a randomized, open-label, parallel-assignment, phase IV trial (&lt;ulink linkID="73848" linkType="Protocol"&gt;NCT01278342&lt;/ulink&gt;; CSMS995BIC03; 2005-005852-42; HOSCAR) evaluating sustained-release high-dose octreotide in combination with a growth hormone receptor antagonist or a dopamine agonist began in patients (expected n = 70) in Europe with acromegaly not controlled by a conventional regimen. The primary endpoint was the percentage of patients experiencing a complete response at 8 months. The trial completed in November 2009. In January 2011, data from the trial were reported. A total of 25, 0 and 9.4% of patients receiving sustained-release high-dose octreotide alone or in combination with pegvisomat or &lt;ulink linkID="2705" linkType="Drug"&gt;cabergoline&lt;/ulink&gt;, respectively, experienced a complete response  [&lt;ulink linkID="1303346" linkType="Reference"&gt;1303346&lt;/ulink&gt;].&lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Obesity&lt;/subtitle&gt;In February 2005, a non-randomized, open-label, single-group assignment, phase IV trial (&lt;ulink linkID="23127" linkType="Protocol"&gt;NCT00171613&lt;/ulink&gt;; CSMS995B2403E1) evaluating octreotide versus saline control began in pediatric hypothalamic obesity patients (expected n = 32) in the US. The primary endpoint was change from baseline in body mass index (BMI). The trial completed in September 2005 [&lt;ulink linkID="1302616" linkType="Reference"&gt;1302616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, a randomized, double-blind, single-group assignment, phase IV trial (&lt;ulink linkID="186612" linkType="Protocol"&gt;NCT00076362&lt;/ulink&gt;; CSMS995B2403) began in pediatric patients (expected n = 60) with hypothalamic obesity in the US. The primary endpoint was the change in BMI from baseline. By February 2006, the trial had completed [&lt;ulink linkID="1303086" linkType="Reference"&gt;1303086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2002, a randomized, double-blind, parallel-assignment, phase II trial (&lt;ulink linkID="38381" linkType="Protocol"&gt;NCT00094146&lt;/ulink&gt;; CSMS995GUS20; US20) began in patients (expected n = 160) in the US with primary insulin hypersecretion and at least moderate obesity. The primary endpoint was the percent change in body weight at 6 months compared with baseline. The trial completed in December 2002 [&lt;ulink linkID="1303108" linkType="Reference"&gt;1303108&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatorenal syndrome&lt;/subtitle&gt;By December 2007, a non-randomized, single-group assignment, open-label, phase II/III trial (&lt;ulink linkID="32533" linkType="Protocol"&gt;NCT00240045&lt;/ulink&gt;; VB-PG-007) had completed in patients (expected n = 9) in Canada with type 2 hepatorenal syndrome and/or refractory ascites. The trial evaluated the combination treatment of &lt;ulink linkID="12538" linkType="Drug"&gt;midodrine&lt;/ulink&gt;, albumin and octreotide LAR versus midodrine, albumin and &lt;ulink linkID="78778" linkType="Drug"&gt;octreotide&lt;/ulink&gt;. The primary endpoint was the improvement in renal function at 1 month [&lt;ulink linkID="1302741" linkType="Reference"&gt;1302741&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatocellular carcinoma&lt;/subtitle&gt;In May 2005, preliminary data from a phase III study of long-acting octreotide, initiated in July 2002, were presented at the 41st ASCO meeting in Orlando, FL. In the multicenter, placebo-controlled trial, 272 patients with  hepatocellular carcinoma not suitable for surgery, percutaneous ablation or chemoembolization were randomized to a monthly im injection of placebo or 30 mg long-acting octreotide. In April 2004, the median overall survival were 6.5 months in the octreotide group and 7.3 months in the placebo group. The interim analysis suggested no survival benefit [&lt;ulink linkID="602913" linkType="Reference"&gt;602913&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2001, a hepatocellular carcinoma trial carried out in Greece, also presented at DDW 2001, Atlanta, GA, showed that long-acting octreotide improved survival and quality of life [&lt;ulink linkID="412005" linkType="reference"&gt;412005&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Neuroendocrine tumors&lt;/subtitle&gt;In  October 2016, clinical data from a prospective multicentre single-arm phase II study (EVERLAR; NCT01567488) which evaluated the efficacy and safety of everolimus and octreotide LAR in patients (n = 44) with advanced non-functioning well-differentiated gastrointestinal-neuroendocrine tumors (GI-NET) were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Median progression-free survival was 11.5 months. Early biochemical response was reported in only six patients with objective response rate and stable disease rate of 4.7 and 83.7%, respectively. Median overall survival (OS) was not reached after 24 months of median follow-up. Overall, the everolimus + octreotide combination provided clinically relevant efficacy in non-functioning GI-NETs [&lt;ulink linkID="1805982" linkType="Reference"&gt;1805982&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, a randomized, double-blind, parallel-assignment, phase III trial (&lt;ulink linkID="41642" linkType="Protocol"&gt;NCT00690430&lt;/ulink&gt;; CSOM230C2303) evaluating &lt;ulink linkID="40061" linkType="Drug"&gt;pasireotide LAR&lt;/ulink&gt; and octreotide LAR in patients whose disease-related symptoms was inadequately controlled by somatostatin analogs began in patients (expected n = 202) in the US with metastatic carcinoid disease. The primary endpoint was efficacy, evaluated by bowel movements and/or flushing. At that time, the trial was estimated to complete in August 2011. In May 2011, the trial was recruiting participants [&lt;ulink linkID="1257230" linkType="Reference"&gt;1257230&lt;/ulink&gt;]. However, by January 2013, the trial had closed based on a futility analysis, which demonstrated that the trial was unlikely to meet its primary endpoint [&lt;ulink linkID="1388709" linkType="Reference"&gt;1388709&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a randomized, double-blind, placebo-controlled, multicenter phase III study (&lt;ulink linkID="29331" linkType="Protocol"&gt;NCT00412061&lt;/ulink&gt;; RADIANT-2; CRAD001C2325) of &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt; in combination with long-acting release octreotide was initiated in patients (n = 429) with advanced carcinoid tumors [&lt;ulink linkID="1116393" linkType="Reference"&gt;1116393&lt;/ulink&gt;]. The endpoints were progression-free survival (PFS) and overall survival (OS) [&lt;ulink linkID="942950" linkType="Reference"&gt;942950&lt;/ulink&gt;], [&lt;ulink linkID="1063130" linkType="Reference"&gt;1063130&lt;/ulink&gt;]. In July 2010, data from the trial were reported showing that the primary endpoint was closely missed (PFS hazard ratio = 0.77 in favor of everolimus, p = 0.026 versus p = 0.024 predefined). The company planned to examine the imbalance observed in baseline between the two treatment arms and discuss the full data with the health authorities [&lt;ulink linkID="1116461" linkType="Reference"&gt;1116461&lt;/ulink&gt;]. Findings from further analyses of the study data were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy, in October 2010. Analyses were conducted using a statistical model to adjust for imbalances in baseline characteristics between the two treatment arms and inconsistencies between the review of radiology scans for disease progression. The results demonstrated that everolimus plus octreotide LAR provided a significant reduction in the risk of disease progression by 40%, versus octreotide LAR alone [&lt;ulink linkID="1137765" linkType="Reference"&gt;1137765&lt;/ulink&gt;]. In February 2011, similar data were published [&lt;ulink linkID="1167084" linkType="Reference"&gt;1167084&lt;/ulink&gt;], [&lt;ulink linkID="1167258" linkType="Reference"&gt;1167258&lt;/ulink&gt;]. In June 2011, additional data were presented at the 47th ASCO annual meeting in Chicago, IL. Patients received everolimus (10 mg/day; n = 216) or placebo (n = 213), both in combination with octreotide LAR (30 mg) every 28 days. Data showed that the median PFS in the everolimus and placebo groups were 16.4 and 11.3 months, respectively; median PFS for patients with elevated CgA and non-elevated CgA was 13.9 and 31.3 months, and 8.4 and 20.1 months, respectively, for the everolimus and placebo groups. CgA and 24-h urinary 5-hydroxyindole acetic acid (5-HIAA) responses (&amp;gt;/= 50% reduction from baseline/normalization) were seen in 45.7 and 60.7% of patients, respectively, in the everolimus group, compared with 28.8 and 46.8%, respectively, in the placebo group. Patients with elevated levels of CgA and 5-HIAA at baseline when treated with everolimus + octreotide LAR, showed a significant reduction in serum CgA and 24-h urinary 5-HIAA levels compared with placebo + octreotide LAR. After first cycle of treatment, the least square mean estimates for the ratio of change from baseline in CgA and 5-HIAA in everolimus + octreotide LAR versus placebo + octreotide LAR groups were 0.85 and 0.84, respectively. The positive effects of everolimus plus octreotide LAR treatment was sustained over time [&lt;ulink linkID="1196459" linkType="Reference"&gt;1196459&lt;/ulink&gt;], [&lt;ulink linkID="1195558" linkType="Reference"&gt;1195558&lt;/ulink&gt;], [&lt;ulink linkID="1195559" linkType="Reference"&gt;1195559&lt;/ulink&gt;], [&lt;ulink linkID="1196696" linkType="Reference"&gt;1196696&lt;/ulink&gt;]. In September 2011, further data were presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. Everolimus plus octreotide combination therapy achieved a 23% reduction in the risk of progression. The PFS was 12 and 8.6 months for the everolimus and placebo groups, respectively according to a local investigator assessment; and a 22% reduction in the risk of progression was achieved in the everolimus arm. Everolimus achieved a median overall survival of 30.5 months compared with 33.5 months for placebo [&lt;ulink linkID="1224029" linkType="Reference"&gt;1224029&lt;/ulink&gt;]. At that time, data from an exploratory analysis evaluating the effect of previous somatostatin analog (SSA) therapy on PFS were also presented at the European Multidisciplinary Cancer Congress in Stockholm, Sweden. In patients treated with everolimus plus octreotide LAR, the PFS was 14.3 months for patients who had received prior SSA therapy, compared with 25.2 months for patients who had not received prior SSA therapy. The overall median PFS was 18.63 and 14.03 months for the everolimus and placebo groups, respectively in patients with the small intestine as the primary tumor site; PFS was longer in the everolimus arm compared with the placebo arm regardless of prior SSA therapy. The median PFS in SSA-naive patients with small intestine neuroendocrine tumors receiving placebo was 22.74 months. In a subgroup analysis assessing the efficacy of everolimus plus octreotide LAR in patients with advanced lung neuroendocrine tumors, the median PFS was 13.63 and 5.59 months for the everolimus and placebo arms, respectively; a 28% reduction in the estimated risk of progression was observed for the everolimus arm. In the everolimus and placebo arms, a reduction in the target lesion from baseline was observed in 67 and 27% of patients, respectively [&lt;ulink linkID="1224031" linkType="Reference"&gt;1224031&lt;/ulink&gt;], [&lt;ulink linkID="1224037" linkType="Reference"&gt;1224037&lt;/ulink&gt;].  In January 2014, clinical data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco, CA. By primary tumor location, treatment-naive patients had PFS of 5.7, 22.2 months and not reached for the foregut, midgut and hindgut, respectively; these respective values for treatment-experienced patients were 8.7, 12 and 6.6 months. The median overall survival was 35.2 months in the overall population, 50.6 months in treatment-naive patients and 33 months in treatment-experienced patients [&lt;ulink linkID="1517517" linkType="Reference"&gt;1517517&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2001, a randomized, double-blind, parallel-group phase IIIb trial (&lt;ulink linkID="29531" linkType="Protocol"&gt;NCT00171873&lt;/ulink&gt;; PROMID) was initiated in 85 patients with metastasized neuroendocrine tumors of the mid-gut at 18 sites in Germany. Patients were to receive long-acting octreotide depot or placebo. The primary endpoint was time-to-progression. In May 2008, the trial was ongoing, but not recruiting patients [&lt;ulink linkID="976470" linkType="Reference"&gt;976470&lt;/ulink&gt;], [&lt;ulink linkID="976256" linkType="Reference"&gt;976256&lt;/ulink&gt;]. In January 2009, interim data were presented at the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology in San Francisco, CA, which showed that the drug had an antitumor benefit.  A significant 66% reduction in the risk of disease progression was observed after six months in patients receiving long-acting octreotide compared with patients taking placebo. Tumor growth was stopped in 69% of patients taking long-acting octreotide compared with 39% of patients receiving placebo. No tumor progression was observed for a median of 14.3 months in patients receiving the drug, compared with 6 months for patients taking placebo. Drug treatment benefited patients with hormone-secreting (functioning) and non-secreting (non-functioning) tumors. The safety findings from the study were consistent with those observed previously [&lt;ulink linkID="976256" linkType="Reference"&gt;976256&lt;/ulink&gt;].  In  June 2009,  similar data were presented at the 45th ASCO meeting in Orlando, FL [&lt;ulink linkID="1007635" linkType="Reference"&gt;1007635&lt;/ulink&gt;]. In October 2009, similar data from the trial were published [&lt;ulink linkID="1046390" linkType="Reference"&gt;1046390&lt;/ulink&gt;], [&lt;ulink linkID="1046798" linkType="Reference"&gt;1046798&lt;/ulink&gt;]. In June 2013, further data were presented at the 49th ASCO meeting in Chicago, IL. The median time to progression (TTP) in octreotide and placebo groups were 27.14 and 7.21 months, respectively. In patients with low tumor load of &amp;lt;/=10%, the anti-proliferative effect was more pronounced. The total numbers of events of OS in octreotide (n = 42) and placebo (n = 43) groups were 19 and 22 events, respectively. The median OS in the octreotide (n = 10) and placebo (n = 11) groups with hepatic tumor load of &amp;gt;10% were 35.45 and 83.71 months, respectively [&lt;ulink linkID="1426222" linkType="Reference"&gt;1426222&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2017, results from an open-label, multicenter, randomized phase II study (n = 7 and 5 acromegaly and NET patients, respectively) were presented at 99th Endocrine Society Annual Meeting in Orlando, FL. Patients treated for &amp;gt;/= 2 months with a stable dose of long-acting im octreotide 10 (arm A), 20 (arm B) or 30 mg (arm C) q4w received a last dose of LA octreotide in period 0 and were randomized 28 days later to receive &lt;ulink linkID="54478" linkType="Drug"&gt;octreotide sc depot&lt;/ulink&gt; 10 mg q2w (arm D) or 20 mg q4w (arm E) for 3 months (period 1). Cmax and AUC (0 to 28) were found to be significantly higher in arms D and E compared with arms A, B and C in both acromegaly and NET groups, whereas a similar Ctrough was observed with arms D and E and arms B and C. Gastrointestinal disorders (diarrhea, nausea), injection site pain and headache were the most common AEs observed in period 1. There was no requirement for rescue medication for NET symptom control during the study [&lt;ulink linkID="1913253" linkType="Reference"&gt;1913253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, an open-label, single group assignment, phase II trial (&lt;ulink linkID="142927" linkType="Protocol"&gt;NCT01886287&lt;/ulink&gt;; MCC-17410) was planned to be initiated in the US  to investigate the effects of high-dose octreotide on flushing, diarrhea, and quality of life in patients (expected n = 30) with carcinoid syndrome whose disease-related symptoms are inadequately controlled by the maximum approved dose of octreotide LAR. The trial was expected to be initiated and completed by August 2013 and April 2018, respectively. The primary endpoint was frequency of symptoms. In December 2013, the trial began [&lt;ulink linkID="1457137" linkType="Reference"&gt;1457137&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2001,  results were presented at DDW 2001, Atlanta, GA, of a prospective trial in 15 gastronoma patients carried out by the National Institute of Diabetes and Digestive and Kidney Diseases were presented. Over 1.5 years, long-acting octreotide was able to control gastrinoma growth in 46% of patients with progressive disease, was more effective than chemotherapy, and was well tolerated in 80% of patients [&lt;ulink linkID="408897" linkType="reference"&gt;408897&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 2001, data were presented on long-acting octreotide claiming that combination therapy with interferon might be useful for the treatment of metastatic neuroendocrine tumors [&lt;ulink linkID="411007" linkType="reference"&gt;411007&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At DDW 2000 in San Diego, CA, the efficacy, safety and tolerability of long-acting octreotide was investigated in 17 patients with various forms of neuroendocrine tumor and was found to be as effective and safe as octreotide when administered once every 28 days [&lt;ulink linkID="366686" linkType="reference"&gt;366686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Thymoma&lt;/subtitle&gt;In September 2005, an open-label, single-group assignment, phase II (&lt;ulink linkID="24014" linkType="Protocol"&gt;NCT00332969&lt;/ulink&gt;; CSMS995ADE13) began in patients (expected n = 25) in Germany with primary inoperable thymoma. The primary endpoints were the shrinkage of tumor size and diameter over 6 months. In October 2010, the trial had completed [&lt;ulink linkID="1302719" linkType="Reference"&gt;1302719&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Variceal bleeding&lt;/subtitle&gt;In May 2001, studies were presented at DDW in Atlanta, GA, investigating the use of long-acting octreotide in prevention of variceal bleeding, a complication of cirrhosis. The placebo-controlled trial involved 39 patients assessed to be at low risk of variceal bleeding, and failed to demonstrate any significant decrease in hemodynamic parameters with either 10 or 30 mg long-acting octreotide [&lt;ulink linkID="408782" linkType="reference"&gt;408782&lt;/ulink&gt;], [&lt;ulink linkID="412150" linkType="reference"&gt;412150&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Short bowel syndrome&lt;/subtitle&gt;In May 2000, results were presented from a trial of long-acting octreotide in eight SBS patients at DDW 2000 in San Diego, CA. Over 15 weeks, long-acting octreotide reduced gastrointestinal transit time but no effects were observed on fecal water and fat content [&lt;ulink linkID="366380" linkType="reference"&gt;366380&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Acromegaly&lt;/subtitle&gt;In July 2002, a non-randomized, single-group assignment, open-label, phase IV trial (&lt;ulink linkID="14205" linkType="Protocol"&gt;NCT00171886&lt;/ulink&gt;; CSMS995BES02) evaluating first-line octreotide began in patients (expected n = 20) in Spain with  acromegaly and a pituitary macroadenoma or microadenoma. The primary endpoint was decrease in growth hormone and IGF-1 levels from baselines to weeks 12, 24 and 48. However, by September 2005, the trial had been suspended [&lt;ulink linkID="1303153" linkType="Reference"&gt;1303153&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, a randomized, double-blind, parallel-assignment, phase III trial (&lt;ulink linkID="67068" linkType="Protocol"&gt;NCT01137682&lt;/ulink&gt;; CSOM230C2402; EUDRACT 2009-016722-13; PAOLA) evaluating &lt;ulink linkID="40061" linkType="Drug"&gt;pasireotide LAR&lt;/ulink&gt; 40 and 60 mg versus octreotide LAR or lanreotide autogel began in patients (expected n = 186)  with inadequately controlled acromegaly. The primary endpoints were the mean growth hormone and IGF-1 levels at 24 weeks. At that time, the trial was estimated to complete in June 2013. In November 2011, the trial was recruiting participants [&lt;ulink linkID="1257223" linkType="Reference"&gt;1257223&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By April 2008, a global, 330-patient, 12-month, randomized, double-blind, active-controlled, parallel-assigned, safety and efficacy, phase III trial (&lt;ulink linkID="14214" linkType="Protocol"&gt;NCT00600886&lt;/ulink&gt;; CSOM230C2305) for acromegaly had begun. The primary endpoint was mean growth hormone level and insulin like growth factor-1 level. Secondary endpoints were the comparison of &lt;ulink linkID="40061" linkType="Drug"&gt;pasireotide LAR&lt;/ulink&gt; and octreotide LAR on change from baseline in mean growth hormone [&lt;ulink linkID="898523" linkType="Reference"&gt;898523&lt;/ulink&gt;], [&lt;ulink linkID="898822" linkType="Reference"&gt;898822&lt;/ulink&gt;]. By December 2009, enrollment had been completed [&lt;ulink linkID="1063130" linkType="Reference"&gt;1063130&lt;/ulink&gt;]. In April 2011, Novartis reported that the trial had met the primary endpoint, demonstrating that pasireotide treatment normalized IGF-1 and growth hormone levels [&lt;ulink linkID="1185126" linkType="Reference"&gt;1185126&lt;/ulink&gt;]. In May 2012, data from the 358-patient PASPORT-ACROMEGALY study were presented at the joint 15th International Congress of Endocrinology and 14th European Congress of Endocrinology meeting (ICE/ECE) in Florence, Italy. Achievement of disease control was 63% more likely in the pasireotide arm than the octreotide LAR (31.3 versus 19.2% of patients met the primary endpoint in the two arms, respectively). Data from the 6-month extension study, in which patients not achieving full biochemical control after 12 months could switch therapy, showed that 21% of patients switching to pasireotide achieved control, compared with 2.6% of those switching to octreotide LAR [&lt;ulink linkID="1288148" linkType="Reference"&gt;1288148&lt;/ulink&gt;]. In June 2012, similar clinical data were presented at the 94th Annual Meeting of the Endocrine Society in Houston, TX; at the initiation of the extension phase biochemical control rates were 62.2 and 52.2% in patients receiving pasireotide and octreotide, respectively, and 45.9 patients 45.7% maintained biochemical control at month 19, respectively [&lt;ulink linkID="1303179" linkType="Reference"&gt;1303179&lt;/ulink&gt;], [&lt;ulink linkID="1303793" linkType="Reference"&gt;1303793&lt;/ulink&gt;]. Also at this meeting further clinical data were presented . In the core trial at month 12, a greater proportion of patients receiving pasireotide than octreotide had biochemical control of disease (31.3 versus 19.2%, respectively; p = 0.007) and full response (35.8 versus 20.9%, respectively), resulting in improvements by 7.0 points in the mean acromegaly quality-of-life scores compared to an improvement by 4.9 points with acromegaly [&lt;ulink linkID="1303176" linkType="Reference"&gt;1303176&lt;/ulink&gt;], [&lt;ulink linkID="1303793" linkType="Reference"&gt;1303793&lt;/ulink&gt;]. In a report of clinical data from a post-hoc analysis also presented at this meeting, the benefits of pasireotide over octreotide were independent from baseline tumor volume. Response rates at 12 months were consistently greater with pasireotide than with octreotide in patients with a tumoral volume &amp;lt;/= 372 to 2656 mm3, and similar in patients with a baseline tumor volume &amp;gt; 2656 mm3 [&lt;ulink linkID="1303173" linkType="Reference"&gt;1303173&lt;/ulink&gt;], [&lt;ulink linkID="1303793" linkType="Reference"&gt;1303793&lt;/ulink&gt;]. Also at the same meeting, clinical data reported demonstrated that in patients switching from octreotide to pasireotide at the end of the core study, 21% achieved biochemical control, compared with 2.6% of patients attaining control upon switch to octreotide from pasireotide [&lt;ulink linkID="1303140" linkType="Reference"&gt;1303140&lt;/ulink&gt;], [&lt;ulink linkID="1303793" linkType="Reference"&gt;1303793&lt;/ulink&gt;]. Also at the meeting is was confirmed that the proportion of patients with growth hormone levels &amp;lt;2.5 microg/l was similar with the two treatments, but pasireotide was associated with a significantly higher proportion of patients with normal IGF-1 levels [&lt;ulink linkID="1303409" linkType="Reference"&gt;1303409&lt;/ulink&gt;], [&lt;ulink linkID="1304431" linkType="Reference"&gt;1304431&lt;/ulink&gt;]; in June 2013, similar data were presented at the 95th ENDO Annual Meeting in Boston, MA, USA [&lt;ulink linkID="1437141" linkType="Reference"&gt;1437141&lt;/ulink&gt;], [&lt;ulink linkID="1437170" linkType="Reference"&gt;1437170&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2002, a non-randomized, single-group assignment, open-label, phase III trial (&lt;ulink linkID="7059" linkType="Protocol"&gt;NCT00128232&lt;/ulink&gt;; CSMS995B2401) began in patients (expected n = 100) in Germany with previously untreated acromegaly. The primary endpoint was mean levels of growth hormone and IGF-1 at baseline and weeks 12, 24 and 48. The trial completed in August 2004 [&lt;ulink linkID="1303127" linkType="Reference"&gt;1303127&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, a randomized, parallel-assignment, open-label, phase III trial (&lt;ulink linkID="7006" linkType="Protocol"&gt;NCT00225979&lt;/ulink&gt;; CSMS995B2402) began evaluating octreotide versus surgery in treatment-naive patients (expected n = 100) in Italy with acromegaly. The trial completed in March 2005 [&lt;ulink linkID="1303146" linkType="Reference"&gt;1303146&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, results from an open-label, multicenter, randomized phase II study (n = 7 and 5 acromegaly and NET patients, respectively) were presented at 99th Endocrine Society Annual Meeting in Orlando, FL. Patients treated for &amp;gt;/= 2 months with a stable dose of long-acting im octreotide 10 (arm A), 20 (arm B) or 30 mg (arm C) q4w received a last dose of LA octreotide in period 0 and were randomized 28 days later to receive octreotide sc depot 10 mg q2w (arm D) or 20 mg q4w (arm E) for 3 months (period 1). Cmax and AUC (0 to 28) were found to be significantly higher in arms D and E compared with arms A, B and C in both acromegaly and NET groups, whereas a similar Ctrough was observed with arms D and E and arms B and C. In acromegaly patients, a grade 2 erythema was reported on day 29 in one patient in arm D, along with few episodes of mild (grades 1) erythema and swelling [&lt;ulink linkID="1913253" linkType="Reference"&gt;1913253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, clinical data from a randomized, open-label, single-dose, single-center, parallel-arm, phase I study were presented at the 39th European Society for Medical Oncology congress in Madrid, Spain. Subjects (n = 106) were randomized (1:1) to receive octreotide LAR (current vehicle, 30 mg; n = 52) or SMS-995L (new vehicle, 30 mg; n =54) for 14 weeks and a final safety follow-up was at week 18. Both the formulations had similar pharmacokinetic release profiles and were found to be bioequivalent, safe and well tolerated   [&lt;ulink linkID="1597349" linkType="Reference"&gt;1597349&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014,  data from a randomized, open-label, repeat-dose phase I study were presented at the 16th ICE/96th ENDO Joint conference in Chicago, IL. A steady and rapid increase in Cmax was reported with octreotide fluid crystal (FC), followed by a slow and exponential decrease in concentration to day 28. The mean Cmax was 29.3 ng/ml, mean AUC (28 day) was 3465 h.ng/ml and median Tmax was 24 h, after the third injection of octreotide FC. The mean Cmax was 1.8 ng/ml, mean AUC (28 day) was 733 h.ng/ml and median Tmax was 1 h, after the third injection of octreotide LAR. Compared with octreotide LAR, the relative bioavailability of octreotide FC was 487%. Octreotide FC showed more rapid and greater IGF-1 suppression compared with octreotide LAR during weeks 1 to 2  [&lt;ulink linkID="1571251" linkType="Reference"&gt;1571251&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;Results from an international multicenter trial of long-acting octreotide in 125 acromegalics, reported in June 1999, confirmed that levels of the hormones associated with acromegaly are significantly decreased in treated patients [&lt;ulink linkID="328007" linkType="reference"&gt;328007&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Emesis&lt;/subtitle&gt;In September 2005, a randomized, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="17849" linkType="Protocol"&gt;NCT00332696&lt;/ulink&gt;; CSMS995AFR08) began in patients (expected n = 64) in France with symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis. The primary endpoints were the number of patients demonstrating treatment success of less than two vomiting episodes on average per day from day 10 to 13, no use of a nasogastric tube since at least day 10 and no use of an anticholinergic agent until day 14. In September 2008, the trial had completed [&lt;ulink linkID="1303259" linkType="Reference"&gt;1303259&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Diabetic retinopathy&lt;/subtitle&gt;By  April 2006, Novartis had terminated the development of the compound for the indication based on results from two phase III trials [&lt;ulink linkID="663540" linkType="Reference"&gt;663540&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, clinical data were presented at the Sixth ISOPT meeting in Berlin, Germany. Reduced progression to high-risk proliferative diabetic retinopathy was seen after sc administration of 200 to 5000 microg/day for 15 months. Reduction in vitreal hemorrhage after laser photocoagulation was also noted. At that time, phase III studies CSMS995-0802 (a European trial in 585 patients) and CSMS995-0804 (313 patients in the US, Canada and Brazil) were further investigating this new use  [&lt;ulink linkID="661755" linkType="Reference"&gt;661755&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By the end of 1998, long-acting octreotide was in phase III trials for the treatment of proliferative diabetic retinopathy [&lt;ulink linkID="319337" linkType="reference"&gt;319337&lt;/ulink&gt;]. These were ongoing at the end of 1999, with Novartis predicting that the compound would be filed for this indication after 2002 [&lt;ulink linkID="342937" linkType="reference"&gt;342937&lt;/ulink&gt;], [&lt;ulink linkID="364082" linkType="reference"&gt;364082&lt;/ulink&gt;]. From late 2001 to early 2003, launch was expected in 2005 for this indication [&lt;ulink linkID="427419" linkType="reference"&gt;427419&lt;/ulink&gt;], [&lt;ulink linkID="491099" linkType="reference"&gt;491099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In October 2018, data from a phase II, randomized, parallel-group, multicenter, open-label study (&lt;ulink linkID="216211" linkType="Protocol"&gt;NCT02294786&lt;/ulink&gt;; RELATED) which evaluated the clinical benefit of the prophylactic use of octreotide to prevent or reduce the frequency and severity of diarrhea associated with lapatinib + capecitabine treatment in patients (n = 62) with HER2+ metastatic breast cancer were presented at the 2018 ESMO Congress in Munich, Germany. The primary endpoint was not met, and the study was stopped at the interim analysis; and prophylactic octreotide did not reduce the proportion of patients experiencing grade &amp;gt;/= 2 diarrhea. In octreotide + lapatinib + capecitabine and lapatinib + capecitabine arms, the reported rates of overall response was 20 and 19%; clinical benefit response was 23 and 28%; complete response was 0 and 6; partial response was 20 and 13%; stable disease of &amp;gt;/=24 weeks was 3 and 9%; stable disease of &amp;lt;24 weeks was 10 and 6%; progressive disease was 47 and 53%, respectively [&lt;ulink linkID="2084543" linkType="Reference"&gt;2084543&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The long-acting octreotide depot uses a poly(lactide-co-glycolide) based microsphere delivery system to provide a slow release of octreotide from the site of injection. Unlike octreotide, which is administered three times a day, the long-acting octreotide depot is only administered once a month [&lt;ulink linkID="311466" linkType="reference"&gt;311466&lt;/ulink&gt;], [&lt;ulink linkID="479003" linkType="reference"&gt;479003&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2004-06-30T00:00:00.000Z</StatusDate><Source id="1301752" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2011-12-31T00:00:00.000Z</StatusDate><Source id="1229980" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2012-02-12T00:00:00.000Z</StatusDate><Source id="2065870" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="54">Carcinoma</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1667">Gigantism</Indication><StatusDate>2004-06-30T00:00:00.000Z</StatusDate><Source id="1301752" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-01-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1667">Gigantism</Indication><StatusDate>2014-01-09T00:00:00.000Z</StatusDate><Source id="1514150" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2014-01-09T00:00:00.000Z</StatusDate><Source id="1514150" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1998-03-18T00:00:00.000Z</StatusDate><Source id="281429" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2004-06-30T00:00:00.000Z</StatusDate><Source id="1301752" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2012-02-12T00:00:00.000Z</StatusDate><Source id="2065870" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1999-06-17T00:00:00.000Z</StatusDate><Source id="328281" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="576">Diabetic retinopathy</Indication><StatusDate>2006-04-24T00:00:00.000Z</StatusDate><Source id="663540" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>1999-05-18T00:00:00.000Z</StatusDate><Source id="325966" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>1997-12-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2212">Hepatorenal syndrome</Indication><StatusDate>2009-06-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2004-01-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate>2006-08-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2939">Thymoma</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="GR">Greece</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2212">Hepatorenal syndrome</Indication><StatusDate>2002-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="110">Emesis</Indication><StatusDate>2010-04-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2168">Short bowel syndrome</Indication><StatusDate>2001-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2179">Varices</Indication><StatusDate>2002-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2011-11-25T00:00:00.000Z</StatusDate><Source id="1243211" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1667">Gigantism</Indication><StatusDate>2004-04-23T00:00:00.000Z</StatusDate><Source id="537736" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1988-10-25T00:00:00.000Z</StatusDate><Source id="311483" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2002-11-04T00:00:00.000Z</StatusDate><Source id="469331" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2004-04-23T00:00:00.000Z</StatusDate><Source id="537736" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2212">Hepatorenal syndrome</Indication><StatusDate>2005-10-13T00:00:00.000Z</StatusDate><Source id="1302741" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2212">Hepatorenal syndrome</Indication><StatusDate>2007-12-15T00:00:00.000Z</StatusDate><Source id="1302741" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16018">Novartis Pharma KK</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate>2002-01-31T00:00:00.000Z</StatusDate><Source id="1303108" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24481">Sandoz Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1995-06-30T00:00:00.000Z</StatusDate><Source id="1288148" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1996-12-31T00:00:00.000Z</StatusDate><Source id="311510" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2002-07-31T00:00:00.000Z</StatusDate><Source id="602913" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2006-01-10T00:00:00.000Z</StatusDate><Source id="1116393" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2008-04-30T00:00:00.000Z</StatusDate><Source id="898822" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2008-04-30T00:00:00.000Z</StatusDate><Source id="898822" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2008-04-30T00:00:00.000Z</StatusDate><Source id="898822" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1667">Gigantism</Indication><StatusDate>2013-05-17T00:00:00.000Z</StatusDate><Source id="1514537" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2013-05-17T00:00:00.000Z</StatusDate><Source id="1514537" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1998-12-31T00:00:00.000Z</StatusDate><Source id="776665" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>1998-12-31T00:00:00.000Z</StatusDate><Source id="776665" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate>2004-03-31T00:00:00.000Z</StatusDate><Source id="1303086" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2179">Varices</Indication><StatusDate>2001-05-23T00:00:00.000Z</StatusDate><Source id="412150" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2939">Thymoma</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="1302719" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="110">Emesis</Indication><StatusDate>2005-09-30T00:00:00.000Z</StatusDate><Source id="1303259" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2006-01-11T00:00:00.000Z</StatusDate><Source id="1116393" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2012-02-12T00:00:00.000Z</StatusDate><Source id="2065870" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2012-02-12T00:00:00.000Z</StatusDate><Source id="2065870" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="5">Acromegaly</Indication><StatusDate>2002-11-04T00:00:00.000Z</StatusDate><Source id="469331" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>2011-05-18T00:00:00.000Z</StatusDate><Source id="1243211" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1128">Neuroendocrine tumor</Indication><StatusDate>1999-09-13T00:00:00.000Z</StatusDate><Source id="339358" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="576">Diabetic retinopathy</Indication><StatusDate>1999-05-01T00:00:00.000Z</StatusDate><Source id="319337" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1667">Gigantism</Indication><StatusDate>2002-11-04T00:00:00.000Z</StatusDate><Source id="469331" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17278">Italfarmaco SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="102">Diarrhea</Indication><StatusDate>1996-02-01T00:00:00.000Z</StatusDate><Source id="213146" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="AU">Australia</Country><Indication id="1128">Neuroendocrine tumor</Indication><AwardedIndication>For the treatment of patients with advanced neuroendocrine tumours of the midgut or unknown primary tumour location.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-09-15T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="1128">Neuroendocrine tumor</Indication><AwardedIndication>Treatment of neuroendocrine tumors</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-08-05T00:00:00.000Z</MileStoneDate><Source id="1219114" type="OTHER"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="AU">Australia</Country><Indication id="1128">Neuroendocrine tumor</Indication><AwardedIndication>For treatment of patients with symptoms associated with: · functional gastro-entero-pancreatic neuroendocrine tumours (GEP/NETs); · Glucagonomas; · Gastrinomas/Zollinger-Ellison syndrome; · Insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy; and · GRFomas.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2009-05-15T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="102">Diarrhea</Indication><AwardedIndication>Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1998-08-24T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="5">Acromegaly</Indication><AwardedIndication>Treatment of acromegaly.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1998-08-24T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="23137">Novartis AG</OwnerCompany><Country id="US">US</Country><Indication id="102">Diarrhea</Indication><AwardedIndication>Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1998-08-24T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01753"><Name>Somatostatin receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2116311" linkType="reference" linkID="2116311"&gt;2116311&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)Cc2c[nH]c3c2cccc3)Cc4ccccc4)NC(=O)[C@@H](Cc5ccccc5)N)C(=O)N[C@H](CO)[C@@H](C)O)O</Smiles><Smiles>C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)Cc2c[nH]c3c2cccc3)Cc4ccccc4)NC(=O)[C@@H](Cc5ccccc5)N)C(=O)N[C@H](CO)[C@@H](C)O)O.CC(=O)O</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1052287" number="EP-00374089" title="Use Of Somatostatin Derivatives As Lung Protecting Agents"/><PatentFamily id="1079186" number="CA-02473412" title="Liquid pharmaceutical injectable formulation of octreotide"/><PatentFamily id="1146624" number="RU-02341282" title="Pharmaceutical composition of pancreatropic activity and method of pharmaceutical composition production"/><PatentFamily id="1155658" number="CN-100335497" title="Process for solid phase synthesis of octreotide"/><PatentFamily id="1169116" number="CA-02309312" title="The process for preparing octreotide and derivatives thereof"/><PatentFamily id="1169926" number="WO-00143776" title="Pharmaceutical Formulation For Intravenous Or Intramuscular Octreotide Administration"/><PatentFamily id="1228355" number="UA-00015869" title="Method for conservative treatment of bleeding from injured spleen"/><PatentFamily id="1251311" number="WO-2006077362" title="Pharmaceutical lipid compositions"/><PatentFamily id="1274625" number="EP-00462071" title="Pharmaceutical resorption-improved somatostatin compositions, their preparation and use."/><PatentFamily id="1280825" number="US-05889146" title="Method for synthesis of bifunctional chelating agents-peptides"/><PatentFamily id="128257" number="WO-09808528" title="Method of inhibiting fibrosis with a somatostatin agonist."/><PatentFamily id="1309733" number="WO-2007110765" title="Processes for the preparation of octreotide"/><PatentFamily id="1316022" number="WO-09747317" title="Combination of a somastatin analogue and a rapamycin."/><PatentFamily id="1381694" number="US-20100203014" title="Zwitterionic buffered acidic peptide and protein formulations"/><PatentFamily id="1402421" number="CN-101474397" title="Injection for treating hyperthyroidism"/><PatentFamily id="1403340" number="WO-2009148580" title="Controlled release copolymer formulation with improved release kinetics"/><PatentFamily id="1419360" number="GB-08318552" title="Organic Compounds"/><PatentFamily id="1423788" number="GB-02193891" title="Nasal pharmaceutical compositions containing octreotide."/><PatentFamily id="1438303" number="WO-2005110369" title="Sustained-release microspheres and methods of making and using same"/><PatentFamily id="1511443" number="WO-2005021023" title="Therapeutical conversion"/><PatentFamily id="1551381" number="RU-02403914" title="Method of choosing postoperative modality for medullary carcinoma of thyroid"/><PatentFamily id="155796" number="NZ-00504932" title="Preparation of octreotide and tyr3-octreotide from thr(ol)(tbu)-2-chlorotrityl resin"/><PatentFamily id="1560934" number="RU-02435780" title="Method for producing cyclic peptide-octreotide"/><PatentFamily id="1560964" number="RU-02441018" title="Method of chromatographic purification of octreotide"/><PatentFamily id="1590028" number="WO-2008066279" title="Preparation method of sustained-release microcapsules having good initial burst inhibiting property and the microcapsules thereby"/><PatentFamily id="1604366" number="WO-2006127214" title="Treating liver diseases"/><PatentFamily id="1613267" number="US-05122520" title="Acid addition salts of amidated taurine or glycine, their preparation and use"/><PatentFamily id="1648579" number="WO-09500126" title="Surface-modified albumin microspheres and pharmaceutical compositions containing them"/><PatentFamily id="1650941" number="WO-09912572" title="Compounds and method for the prevention and treatment of diabetic retinopathy."/><PatentFamily id="1662793" number="EP-01787658" title="Sustained release formulations of somatostatin analogue inhibitors of growth hormone"/><PatentFamily id="1663151" number="WO-2007114697" title="Novel composition for tumor growth control"/><PatentFamily id="1708306" number="WO-2011138565" title="Pharmaceutical combination containing lipoic acid, hydroxycitric acid and a somatostatin as active ingredients"/><PatentFamily id="1709894" number="WO-2012035794" title="Octreotide-modified nano preparation for treatment of cancer or palliative care of cancer"/><PatentFamily id="1752581" number="WO-2006017852" title="Pharmaceutical compositions for controlled release delivery of biologically active compounds"/><PatentFamily id="1759630" number="WO-2005087794" title="Process for octreotide synthesis"/><PatentFamily id="1800515" number="WO-09101126" title="Biodegradable system for regenerating the periodontium"/><PatentFamily id="1822128" number="WO-2009095450" title="Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers"/><PatentFamily id="1829225" number="WO-09963935" title="Rapid Opioid Detoxification Therapy And Anti-Readdiction Therapy"/><PatentFamily id="1879427" number="US-06214792" title="Method for treating acute and severe diarrhea."/><PatentFamily id="1880947" number="WO-2005023224" title="Preparation method for sustained release microspheres using a dual-feed nozzle"/><PatentFamily id="1885427" number="EP-01935433" title="A method for preparing covalent lipid-spacer-peptide conjugates"/><PatentFamily id="1946677" number="US-05922682" title="Polyol esters, their preparation and use in depot forms of pharmacologically active agents"/><PatentFamily id="1962913" number="RU-02196144" title="Protected derivatives of octreotide"/><PatentFamily id="1982771" number="WO-09948517" title="Pharmaceutical Compositions For Prolonged Peptide Release And Preparation Method"/><PatentFamily id="1994318" number="KR-2009074316" title="The somatostatin analogue peptide subject tub method using the solid phase synthesis."/><PatentFamily id="202488" number="US-20100021380" title="Dieghylenetriaminepentaacetic acid (DTPA)-modified ferrofluid, preparation method of the same and uses of the same in preparation of peptide ferrofluid"/><PatentFamily id="2052158" number="EP-01591449" title="A process for the formation of disulfide bonds in cyclic peptides"/><PatentFamily id="205365" number="EP-00816413" title="Pharmaceutical composition comprising a purified polylactide and a hydrophilic or lipophilic drug"/><PatentFamily id="2081062" number="WO-2012054998" title="Method for labelling with radionuclides somatostatin analogs associated with diseases with physiopathogenesis involving somatostatin receptors, reagent for &lt;i&gt;in vivo&lt;/i&gt; and/or &lt;i&gt;in vitro&lt;/i&gt; diagnosis on the basis of somatostatin analogues linked to radionuclides, method for diagnosing &lt;i&gt;in vitro&lt;/i&gt; or &lt;i&gt;in vivo&lt;/i&gt; diseases with physiopathogenesis involving somatostatin receptors, using the thus obtained reagent, and kit containing said reagent for diagnosing diseases with physiopathogenesis involving somatostatin"/><PatentFamily id="210085" number="EP-01164143" title="Process for preparing octreotide and derivatives thereof"/><PatentFamily id="2116057" number="CN-01254484" title="Solid-phase synthesis process of octreotide acetate"/><PatentFamily id="21166" number="WO-09810786" title="Pharmaceutical composition for the treatment of syndrome X of Reaven."/><PatentFamily id="2126650" number="US-08287902" title="Enhanced-diffusion capsule"/><PatentFamily id="2143317" number="US-20080102110" title="Method for preparing lipid-spacer-reactive functional group-peptide"/><PatentFamily id="2154113" number="WO-2012075361" title="In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents"/><PatentFamily id="2168739" number="US-05639480" title="Sustained release formulations of water soluble peptides."/><PatentFamily id="2179261" number="WO-2006108667" title="Method of treatment"/><PatentFamily id="2180822" number="WO-2007071395" title="Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers"/><PatentFamily id="2181355" number="WO-2008008363" title="Pharmaceutical compositions for sustained release delivery of peptides"/><PatentFamily id="2205590" number="WO-00209739" title="Treatment of ocular disorders with somatostatin analogues"/><PatentFamily id="2216302" number="CN-101455845" title="PEG-decorated phospholipid derivative using octreotide as target ligand and production method thereof"/><PatentFamily id="2278333" number="US-20090082259" title="Deuterium-enriched octreotide"/><PatentFamily id="2355536" number="WO-2007141306" title="Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist"/><PatentFamily id="2360988" number="JP-2002047298" title="Novel anticancer agent transmission system"/><PatentFamily id="2449559" number="CN-102850438" title="Solid phase preparation method for octreotide crude product"/><PatentFamily id="2474113" number="WO-2012082618" title="Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules"/><PatentFamily id="2475474" number="WO-2009033660" title="Use of a peptide as a therapeutic agent"/><PatentFamily id="2481674" number="WO-2009079024" title="Improved methods and compositions for F-18 labeling of proteins, peptides and other molecules"/><PatentFamily id="2488807" number="CN-102940609" title="A high encapsulation octreotide slow release microsphere and preparation method thereof"/><PatentFamily id="2497928" number="WO-2006107617" title="Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses"/><PatentFamily id="2497951" number="WO-2009126558" title="Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology"/><PatentFamily id="2504907" number="WO-2011068965" title="Methods and compositions for improved &lt;sup&gt;18&lt;/sup&gt;F labeling of proteins, peptides and other molecules"/><PatentFamily id="2504992" number="WO-2009135015" title="Improved methods and compositions for F-18 labeling of proteins, peptides and other molecules"/><PatentFamily id="2505233" number="WO-2008088648" title="Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules"/><PatentFamily id="2505267" number="WO-03106495" title="Monoclonal antibody hPAM4"/><PatentFamily id="2505883" number="WO-2009055653" title="PEGylation by the dock and lock (DNL) technique"/><PatentFamily id="2557844" number="WO-2013098802" title="Solid phase peptide synthesis via side chain attachment"/><PatentFamily id="2646584" number="WO-2013180310" title="Drug for preventing and/or treating polycystic kidney disease"/><PatentFamily id="2796460" number="WO-2014135590" title="Metallocene compounds and labeled molecules comprising the same for in vivo imaging"/><PatentFamily id="2799892" number="WO-2014142653" title="Vaccination composition"/><PatentFamily id="2821150" number="CN-103965291" title="Preparation method of octreotide, octreotide acetate"/><PatentFamily id="2846731" number="WO-2014197938" title="Combination therapy"/><PatentFamily id="286733" number="CN-01900110" title="Octreotide allosteric peptide molecule and medicine thereof"/><PatentFamily id="290921" number="WO-2005014163" title="Method for loading amphiphile particles with active agents"/><PatentFamily id="2912458" number="JP-2015059105" title="An octreotide analog and a radioactive image-diagnosis agent using the same"/><PatentFamily id="2915310" number="WO-2015051279" title="CXCR4 up- and down-regulation for treatment of diseases or disorders"/><PatentFamily id="2923238" number="WO-2015056805" title="Drug for preventing and/or treating polycystic kidney disease"/><PatentFamily id="2930559" number="JP-06410339" title="Radionuclide label|marker octreotide derivative"/><PatentFamily id="29966" number="WO-03097668" title="Novel process for production of the somatostatin analog, octreotide"/><PatentFamily id="302960" number="WO-2011000848" title="Solid phase peptide synthesis of peptide alcohols"/><PatentFamily id="307644" number="WO-2012083026" title="Branched polyol polyesters, blends and pharmaceutical formulations comprising same"/><PatentFamily id="3105065" number="WO-2016004043" title="Targeted conjugates and particles and formulations thereof"/><PatentFamily id="3113170" number="CN-105168115" title="Oral medication somatostatin analogue polypeptide drug"/><PatentFamily id="312080" number="WO-08802756" title="Peptide Derivatives"/><PatentFamily id="3135374" number="WO-2016028636" title="Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods"/><PatentFamily id="3160737" number="WO-2016054480" title="Venous access catheters and methods for portal venous system catheterization"/><PatentFamily id="3175024" number="JP-2016065050" title="The manufacturing method of an octreotide"/><PatentFamily id="3203609" number="WO-2016094228" title="Implantable drug delivery device"/><PatentFamily id="329509" number="WO-2006099288" title="Controlled release formulations of octreotide"/><PatentFamily id="3318258" number="WO-2016135214" title="α-1-microglobulin for use in the protection of kidneys in radionuclide therapy"/><PatentFamily id="3353490" number="WO-2016140867" title="Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors"/><PatentFamily id="3371831" number="WO-2016146638" title="Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers"/><PatentFamily id="339602" number="UA-00012786" title="Method for producing medicinal agent"/><PatentFamily id="343969" number="WO-2009100216" title="Composition for sustained release delivery of proteins or peptides"/><PatentFamily id="346867" number="WO-2004045633" title="Pharmaceutical composition comprising microparticles"/><PatentFamily id="3487112" number="WO-2016004048" title="Targeted conjugates and particles and formulations thereof"/><PatentFamily id="3548586" number="TW-00375617" title="Novel synthesis of tyr-3-octreotide for radiopharmaceuticals"/><PatentFamily id="3584849" number="CN-106491535" title="A octreotide modified gold spherical shell nano liposome and preparation method thereof"/><PatentFamily id="3606592" number="WO-2017060500" title="Pharmaceutical formulations for the oral delivery of peptide drugs"/><PatentFamily id="363868" number="US-07425542" title="Stabilizing alkylglycoside compositions and methods thereof"/><PatentFamily id="365055" number="WO-2007096055" title="Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes"/><PatentFamily id="3673723" number="CN-106749528" title="Preparation method for octreotide"/><PatentFamily id="369509" number="KR-00991096" title="Manufacturing method of the octreotide using the solid phase systhesis"/><PatentFamily id="3705163" number="WO-2017114384" title="Method for purifying and oxidizing polypeptide containing disulfide bond"/><PatentFamily id="3750004" number="WO-2017136745" title="Oral dosage form with drying agent for delivery of active agent"/><PatentFamily id="3767177" number="WO-2018102974" title="Conjugate for natural active ingredient cardiotonic steroid and octreotide, and preparation method therefor and uses thereof"/><PatentFamily id="3981615" number="CN-107778351" title="A whole solid-phase synthetic method of octreotide"/><PatentFamily id="4024735" number="CN-107899027" title="Neuroendocrine tumour targeting nano-particle imaging agent and preparation method and application thereof"/><PatentFamily id="4121851" number="RU-02657621" title="Method of treatment of pancreatogenic exudative pleurisy"/><PatentFamily id="419789" number="WO-00137784" title="Method For Preventing Diarrhea"/><PatentFamily id="420188" number="WO-2005041901" title="Therapeutics using somatostatin agonists"/><PatentFamily id="4204831" number="WO-2018172494" title="Extruded depot form for prolonged active substance release"/><PatentFamily id="4228836" number="EP-03388053" title="Pharmaceutical formulation and method of preparing the same"/><PatentFamily id="4240311" number="WO-2018195346" title="Drug delivery device with removable pods and related pods, methods and systems"/><PatentFamily id="4262209" number="US-20180326101" title="Compound and pharmaceutical composition for targeted drug delivery"/><PatentFamily id="430958" number="TW-00519545" title="The process for preparing octreotide and derivatives thereof"/><PatentFamily id="4442813" number="WO-2019057087" title="Pharmaceutical constructs with enhanced binding affinity with albumin"/><PatentFamily id="4443119" number="WO-2019058365" title="Somatostatin prodrugs"/><PatentFamily id="446575" number="WO-2012001050" title="Dye compositions and dye syntheses"/><PatentFamily id="4481620" number="IN-201721036278" title="Pharmaceutical composition used for treating acromegaly includes protein or peptide drug, mucoadhesive agent and thermosensitive gelling agent"/><PatentFamily id="4525760" number="WO-2019104225" title="Therapeutic compound formulations"/><PatentFamily id="4546202" number="CN-109824760" title="Octreotide somatostatin precursor compound, ligand compound and its preparation and application"/><PatentFamily id="467896" number="US-06004962" title="Rapid Opioid Detoxification"/><PatentFamily id="523456" number="WO-2010079047" title="Octreotide depot formulation with constantly high exposure levels"/><PatentFamily id="525876" number="RU-02436794" title="Method of producing methyl ether of O-tert-butyl-N-(N-tert-butoxycarbonyl-L-lysyl)-L-threonine"/><PatentFamily id="597570" number="WO-2010079052" title="Nanoparticle compositions"/><PatentFamily id="601126" number="CN-102336808" title="Oxidation cyclization method of octreotide disulfide bond"/><PatentFamily id="619356" number="EP-00029579" title="Novel polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use."/><PatentFamily id="652760" number="WO-2005117830" title="Liquid depot formulations"/><PatentFamily id="662692" number="CN-101396563" title="Chitosan derivative with octreotide as targeted genin and application thereof in preparation"/><PatentFamily id="664493" number="CN-101863961" title="A preparation method of octreotide"/><PatentFamily id="685954" number="WO-09320126" title="Biodegradable Polycarbonates And Their Use As Drug Carriers"/><PatentFamily id="721545" number="WO-2011124031" title="Polypeptide conjugate of paclitaxel or docetaxel"/><PatentFamily id="741061" number="WO-2009100222" title="Non-polymeric compositions for controlled drug delivery"/><PatentFamily id="772194" number="WO-2006041945" title="A counterion exchange process for peptides"/><PatentFamily id="80468" number="WO-2010089757" title="An improved process for synthesis of cyclic octapeptide"/><PatentFamily id="836304" number="WO-09847489" title="Sustained-Release Compositions And Method For Preparing Same"/><PatentFamily id="844011" number="US-20030207811" title="Method of treating retinopathy of prematurity using somatostatin analogs"/><PatentFamily id="85987" number="WO-08707149" title="Pharmaceutical Compositions"/><PatentFamily id="867799" number="EP-00953577" title="Procedure for obtaining the somatostatin analog, octreotide"/><PatentFamily id="869197" number="EP-00657174" title="Use of somatostatin."/><PatentFamily id="876083" number="WO-2005046642" title="Compositions of lipids and cationic peptides"/><PatentFamily id="902042" number="DE-03842688" title="Verwendung Von Somatostatin Zur Behandlung Reaktiver Postprandialer Hypoglykaemien"/><PatentFamily id="908067" number="WO-09317037" title="Treatment of acute migraine or cluster headache attacks."/><PatentFamily id="957946" number="WO-2010011096" title="A polypeptide complex comprising non-peptidyl polymer having three functional ends"/><PatentFamily id="976977" number="US-04798821" title="Antihypertensive therapy for diabetics"/><PatentFamily id="993670" number="WO-2006013369" title="Compositions forming non-lamellar dispersions"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>15</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Italfarmaco SpA" id="17278"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>22</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>23</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></Drug></drugRecordsOutput>